Device for enhancing immunostimulatory capabilities of T-cells
T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.
1. A device for enhancing immunostimulatory capabilities of T-cells comprising:
a universal crosslinking agent comprising a support coated with a first material; and
one or more arrays of second materials capable of binding moieties on the surface of T-cells, wherein the one or more arrays of second materials are crosslinked by the first material of the universal crosslinking agent.
2. The device of claim 1 wherein each of the one or more arrays comprises two or more second materials.
3. The device of claim 1 wherein an array of second materials comprises one or more antibodies that have specificity to a T-cell surface moiety.
4. The device of claim 1 wherein the first material is an antibody.
5. The device of claim 1 wherein the support is a biodegradable support.
6. The device of claim 1 wherein the second materials include mitogenic proteins, monoclonal antibodies, fusion proteins and agents capable of binding to chemokine receptors.
7. The device of claim 1 wherein the second materials in an array are selected from anti-CD3, -CD28, -B7-H3, -PD-L1, -PD-L2, -IL-15R, -CD2, -CD 48, -LFA-1, -CD43, -CD45, -CD4, -CD8, -CD7, -GM1, -LIGHT, -CD27, -OX40, -4-1BB, -CD30, -CD44, -CD31, -CD18/CD11a, -CD29, -CD54, -CD 62L, -VLA4, -IL-2R, -IL-4R, IL-10R, -type II IFNR1 and R2, -type I IFNR, -IL-12beta1 and beta2, -IL-15R, -TNFR1, -TNFR2, and -IL-1R.
8. The device of claim 1 wherein the first material crosslinks at least two arrays of second materials.